Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in ...

Int J Clin Rheumatol. 2010;5(4):407-413.

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to ...

Objective The present study aimed to provide a comprehensive evaluation of the postmarketing safety of belimumab based on the Food and Drug Administration Adverse Event Reporting System (FAERS) ...

Objectives To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse clinical ...

Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in ...

Objectives To evaluate the efficacy and safety of belimumab, targeting BAFF, in patients with pSS. Methods Patients were included in this bi-centric prospective 1-year open-label trial if they ...

It was approved in the US with a similar label last year after priority review, becoming the first oral alternative to GSK's injectable anti-BLyS/BAFF antibody Benlysta (belimumab) for the ...

Saphnelo will compete in the market most closely with GlaxoSmithKline's BLyS inhibitor Benlysta (belimumab), which has been available in the EU to treat SLE since 2011 and recorded worldwide sales ...